Search
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. … [A35677] It was FDA approved on July 20, 2018.[L3770]
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigationalIt is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor
Porfimer sodium
go.drugbank.com/drugs/DB00707ApprovedInvestigationalIt is the first drug to be approved in the use of photodynamic therapy in the United States. … It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent.
Categories: Sensitizers Used in Photodynamic/radiation TherapyInternational brands: Photofrin IICetuximab sarotalocan
go.drugbank.com/drugs/DB19240InvestigationalCetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Chlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnUp to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.
Categories: Drugs Used in DiabetesSynonyms: N-(4-chlorophenylsulfonyl)-N'-propylurea, N-(p-chlorobenzenesulfonyl)-N'-propylureaTamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments. … Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.
Synonyms: (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamineTriamterene
go.drugbank.com/drugs/DB00384ApprovedIt works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. … [L6166] It is also found in a combination product with hydrochlorothiazide that is used for the management of hypertension or treatment of edema in patients who develop hypokalemia on hydrochlorothiazide
Disopyramide
go.drugbank.com/drugs/DB00280ApprovedInvestigationalIt also possesses some anticholinergic and local anesthetic properties. … A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IaAceclofenac
go.drugbank.com/drugs/DB06736ApprovedIt is a more commonly prescribed drug in Europe. … In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug.